Tissue Engineering Market Size:
The global tissue engineering market size reached US$ 18.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 48.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032. The market is driven by the increasing demand for regenerative medicines and TE procedures, rising incidences of fatal road accidents and trauma injuries, the augmenting need for bone implants among patients, continual technological advancements in the field of three-dimensional (3D) tissue engineering, and rising healthcare expenditure.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 18.0 Billion |
Market Forecast in 2032
|
US$ 48.4 Billion |
Market Growth Rate 2024-2032 |
11.3% |
Tissue Engineering Market Analysis:
- Major Market Drivers: Continual advancements in biomaterials and stem cell research are driving the market. Besides this, growing demand for regenerative medicine and organ transplants is impelling the market growth. Furthermore, government funding and support for research initiatives are also bolstering market expansion.
- Key Market Trends: The increased use of 3D printing technology in tissue engineering is a significant trend in the market. In line with this, the development of personalized medicine and patient-specific tissue constructs is also gaining momentum. Also, strategic collaborations between research institutions and biotechnology companies are another significant trend in the market.
- Geographical Trends: North America is leading the tissue engineering market growth due to high investment in healthcare research and development. The region's advanced healthcare infrastructure supports market growth. Favorable regulatory frameworks and numerous clinical trials also contribute to North America's dominance.
- Competitive Landscape: Some of the key market players include AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.
- Challenges and Opportunities: High costs of tissue engineering procedures and materials pose a significant challenge in the market. In addition to this, ethical concerns and regulatory hurdles remain obstacles to market expansion. However, increasing adoption of regenerative medicine is creating lucrative opportunities in the market.
Tissue Engineering Market Trends:
Increasing incidences of chronic diseases
The rising prevalence of chronic diseases, such as cardiovascular disease, diabetes, and orthopedic ailments, has increased the demand for tissue engineering solutions that may repair or replace damaged tissues. Chronic diseases are the leading causes of death and disability worldwide, and they are expected to drive tissue engineering demand throughout the forecast period. Tissue regeneration technology is becoming increasingly popular due to its successful products and low rejection rates. In addition, there is an increasing trend toward more regeneration treatments. Currently, pre-clinical research is focused on the application of tissue-engineered vascular grafts in cardiovascular surgery and treatment. Furthermore, the management of chronic wounds, often resulting from conditions like diabetes, is increasingly utilizing tissue-engineered products to promote faster and more effective healing. Additionally, the rising incidence of chronic respiratory diseases is leading to the development of tissue-engineered lung and airway tissues.
Rapid technological advancements
Technological advancements in the field of 3D tissue engineering, such as the replacement of embryo cells with stem cells, organ-on-a-chip technology, and the use of 3D bioprinters that can efficiently design in vitro implants, are expected to enhance tissue engineering market revenue. In addition, a considerable rise in government funding for medical and academic research activities is anticipated to enhance the growth of the market for tissue engineering throughout the forecast period. The integration of artificial intelligence and machine learning in tissue engineering processes is significantly improving the precision and efficiency of tissue construction. Moreover, collaborations between academic institutions and biotechnology firms are fostering innovation and accelerating the commercialization of advanced tissue-engineered products. For instance, in January 2023, Sartorius, a biopharmaceutical equipment supplier, purchased a 10% investment in 3D bioprinting inventor BICO. Both companies have revealed plans for a collaborative effort.
Rising number of road accidents and trauma injuries
The rising number of road accidents and trauma injuries have been linked to an increase in the development of tissue engineering treatments. This, in turn, is creating a positive tissue engineering market outlook. The number of patients in need of bone implants is increasing as trauma cases and average life spans rise. Approximately 1.19 million lives are lost annually due to road traffic crashes. According to the World health Organization (WHO), between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability. These injuries require medical procedures, resulting in an increasing demand for novel tissue engineering options. The prevalence of road traffic accidents has necessitated advancements in tissue engineering to address complex injury repair. Consequently, healthcare providers are increasingly adopting tissue-engineered products to enhance recovery outcomes and reduce complications associated with traditional treatments. Additionally, the growing geriatric population, which is more susceptible to trauma injuries, further amplifies the need for innovative tissue engineering solutions in the medical field.
Tissue Engineering Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and end user.
Breakup by Type:
- Synthetic Scaffold Material
- Biologically Derived Scaffold Material
- Others
Biologically derived scaffold material dominates the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes synthetic scaffold material, biologically derived scaffold material, and others. According to the report, biologically derived scaffold material represented the largest segment.
The tissue engineering market overview shows that the biologically derived scaffold material is leading the market. Biologically derived scaffolds offer superior biocompatibility and mimic the natural extracellular matrix, promoting better cell attachment, proliferation, and differentiation. This enhances the overall effectiveness of tissue regeneration processes. These materials include naturally occurring polymers including collagen, gelatin, hyaluronic acid, chitosan, and alginate, as well as decellularized extracellular matrix (ECM) scaffolds which are more readily accepted by the body's immune system, reducing the risk of rejection and inflammatory responses compared to synthetic materials. Consequently, the growing preference for these biologically derived materials among researchers and clinicians is resulting in their prominence in the market.
Breakup by Application:
- Orthopedics and Musculoskeletal
- Neurology
- Cardiovascular
- Skin and Integumentary
- Dental
- Others
Orthopedics and musculoskeletal hold the largest share in the market
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes orthopedics and musculoskeletal, neurology, cardiovascular, skin and integumentary, dental, and others. According to the report, orthopedics and musculoskeletal accounted for the largest market share.
The orthopedics and musculoskeletal segment held the highest revenue share during the tissue engineering market forecast period, due to the rising frequency of musculoskeletal illnesses. Furthermore, tissue engineering has emerged as an important therapy option for orthopedic surgeons in the management of various musculoskeletal problems, including meniscal deficiencies in young athletes and osteochondral abnormalities in the glenohumeral joint. According to the World Health Organization (WHO), rheumatoid arthritis affects over 23 million individuals globally. Additionally, significant investments in research and development for orthopedic applications, coupled with technological advancements in biomaterials and regenerative medicine, have led to the introduction of highly effective tissue-engineered products, thereby contributing to growth in this segment.
Breakup by End User:
- Hospitals and Clinics
- Ambulatory Facilities
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics and ambulatory facilities.
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
North America leads the market, accounting for the largest tissue engineering market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for tissue engineering.
North America dominated the market and accounted for the majority of tissue engineering market recent developments, due to the rising awareness regarding stem cell therapy, a growing elderly population, and an increase in chronic illness incidence. Furthermore, sophisticated technology for diagnosing and treating chronic illnesses, the availability of private and government funding, and high healthcare spending are among the factors contributing to its significant proportion. Advancements in 3D tissue engineering technology, as well as the presence of notable market participants, are key drivers of growth through continual product introductions. Moreover, numerous innovations in 3D bioprinting and the expansion of medical tourism are propelling the growth of the market in this region and offering numerous tissue engineering market recent opportunities.
Competitive Landscape:
- The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
- The market is extremely competitive, with many companies competing for the majority of the market share. They are investing heavily in research and development to innovate and improve tissue engineering technologies, focusing on the creation of advanced biomaterials and scaffolds that enhance tissue regeneration and integration. Additionally, collaborations and partnerships with academic institutions, biotechnology firms, and healthcare providers are being established to leverage diverse expertise and accelerate product development. Moreover, several tissue engineering companies are also focusing on upgrading their product portfolios in order to meet the current demand. To meet the growing demand, they are also scaling up their manufacturing capabilities and optimizing production processes for cost-efficiency and higher output.
Tissue Engineering Market News:
- January 16, 2023: BioMed X announced that it has extended its research collaboration with AbbVie, establishing its first US-based institute in New Haven, Connecticut, to focus on immunology and tissue engineering. This expansion aims to develop a new tissue engineering platform for complex human ex vivo models, enhancing the understanding of human disease biology.
- July 11, 2023: Smith+Nephew announced the launch of its REGENETEN Bioinductive Implant in India. This implant is designed to facilitate new tendon-like tissue growth for rotator cuff repair. This collagen-based implant has demonstrated significant clinical success, reducing re-tear rates by 86% compared to conventional surgery alone.
- June 3, 2024: Stryker announced the signing of a definitive agreement to acquire Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. This acquisition will enhance Stryker's portfolio in tissue engineering and repair, demonstrating their commitment to advancing solutions for ligament and tendon reconstruction.
Tissue Engineering Market Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
- Type
- Application
- End User
- Region
|
Types Covered |
Synthetic Scaffold Material, Biologically Derived Scaffold Material, Others |
Applications Covered |
Orthopedics and Musculoskeletal, Neurology, Cardiovascular, Skin and Integumentary, Dental, Others |
End Users Covered |
Hospitals and Clinics, Ambulatory Facilities |
Regions Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation, Zimmer Biomet, etc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the tissue engineering market from 2018-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global tissue engineering market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the tissue engineering industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.